Assessing neuroprotection in Parkinson's disease: From the animal models to molecular neuroimaging in vivo

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 133-141

  Ceravolo, R ^a   Sgado P ^a   Frosini, D ^a   Corsini, G U ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; BETA I 23; CABERGOLINE; CAFFEINE; DJ 1 PROTEIN; DOPAMINE F 18; EPOXOMICIN; GANGLIOSIDE GM1; GPI 1485; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PARAQUAT; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTENONE; SELEGILINE; TRACER; UBIDECARENONE; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

BEHAVIOR; BIOCHEMISTRY; DISEASE COURSE; DISEASE MODEL; DRUG DISTRIBUTION; DRUG MECHANISM; GENE THERAPY; HUMAN; IN VIVO STUDY; MEDICAL RESEARCH; MOLECULAR IMAGING; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; METHODOLOGY; PATHOLOGY;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 34248545495     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_15     Document Type: Review

References (88)

1. Ahlskog J, Uitti R, O'Connor M, et al. (1999) The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson disease. Mov Disord 14: 940-946
2. Ahskog JE (2003) Parkinson's disease: is the initial treatment established. Curr Neurol Neurosci Rep 3: 289-295
3. Alberi L, Sgadò P, Simon HH (2004) Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development 131: 3229-3236
4. Andreassen OA, Ferrante RJ, Dedeoglu DW, et al. (2001) Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp Neurol 167: 189-195
5. Asenbaun S, Bracke T, Pirker W, et al. (1997) Imaging of dopamine transporter with iodine-123-βCIT and SPECT in Parkinson's disease. J Nucl Med 38: 1-6
6. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306
7. Bezard E, Dovero S, Pruiner C, et al. (2001) Relationship between the appearence of symptoms and the level of nigrostriatal degeneration in a progressive 1-methil-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21: 6853-6861
8. Bonifati V, Breedveld GJ, Squitieri F, Vanacore N, Brustenghi P, et al. (2002) Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol 5: 253-256
9. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134
10. Brooks D (2003) Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 53 [Suppl 3]: S110-S119
11. Brooks DJ, Frey KA, Marek KL, et al. (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184: 68-79
12. Ceravolo R, Piccini P, Bailey DL, et al. (2002) 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43: 201-207
13. Corsini GU, Maggio R, Vaglini F (2002) Molecular and cellular events regulating dopamine neuron survival. In: Chiara GD (ed) Handbook of Experimental Pharmacology. Dopamine in the CNS IL Springer-Verlag, Berlin Heidelberg, pp 321-386
14. Dawson TM, Dawson VL (2002) Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat Neurosci 5 [Suppl]: 1058-1061
15. Dawson TM, Dawson VL (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111: 145-151
16. 18F]fluorodopamine in vivo. J Neurosci Methods 76: 157-165
17. Dekker M, Bonifati V, van Swieten J, Leenders N, Galjaard RJ, Snijders P, Horstink M, Heutink P, Oostra B, van Duijn C (2003) Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord. 18: 751-757
18. Dunnett SB, Bjorklund A (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399: A32-A39
19. Emborg ME (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Meth 139: 121-143
20. Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991: 1-14
21. Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404: 394-398
22. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301
23. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272
24. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, et al. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51: 296-301
25. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, et al. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha synuclein. Neuron 34: 521-533
26. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278: 43628-43635
27. Guttman M, Stewart D, Hussey D, et al. (2001) Influence of L-Dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56: 1559-1564
28. Healy DG, Abou-Sleiman PM, Wood NW (2004) Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res 318: 189-194
29. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 7: 427-442
30. Holzmann C, Kruger R, Saecker AM, Schmitt I, Schols L, et al. (2003) Polymorphisms of the alpha-synuclein promoter/expression analyses and association studies in Parkinson's disease. J Neural Transm 110: 67-76
31. Hunot S, Bragg B, Ricard D, et al. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc Natl Acad Sci USA 94: 7531-7536
32. Innis R, Marek K, Sheff K, et al. (1999) Effect of treatment with Levodopa-Carbidopa or L-Selegiline on striatal dopamine transporter SPECT imaging with I[123]β-CIT. Mov Disord 14: 436-442
33. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, et al. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12: 2277-2291
34. Jeon BS, Jackson-Lewis V, Burke RE (1995) 6-Hydroxydopamine lesion of the rat substantia nigra/time course and morphology of cell death. Neurodegeneration 4: 131-137
35. Jiang C, Wan X, He Y, Pan T, Jankovic J, et al. (2005) Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 191: 154-162
36. Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P (2002) Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 52: 849-853
37. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608
38. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108
39. Kuopio A, Marttila RJ, Helenius H, Rinne UK (2001) Familial occurrence of Parkinson's disease in a community-based case-control study. Parkinsonism Relat Disord 7: 297-303
40. 18F)fluorodopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 13: 43-56
41. Lang AE, Benabid AL, Koller WC, et al. (1995) The Core Assessment Program Intracerebral Transplantion. Mov Disord 10: 527-528
42. Langsten JW, Ballard P, Tetrad JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
43. Le W, Conneely OM, Zou L, He Y, Saucedo-Cardenas O, et al. (1999) Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol 159: 451-458
44. Le WD, Xu P, Jankovic J, Jiang H, Appel SH, et al. (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33: 85-89
45. Lee MK, Stirling W, Xu Y, Xu X, Qui D, et al. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53- > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99: 8968-8973
46. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452
47. Liu A, Joyner AL (2001) EN and GBX2 play essential roles downstream of FGF8 in patterning the mouse mid/hindbrain region. Development 128: 181-191
48. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K (1999) Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56: 334-347
49. Marek KL, Seibyl JP, Zoghbi SS, et al. (1996) [123I]β CIT/SPECT imaging demonstrates bilateral loss of dopamine transporter in hemiParkinson's disease. Neurology 46: 231-237
50. Martinez-Martin P, Gil Nagel A, Gracia LM, et al. (1994) Unified Parkinson's disease rating scale: characteristic and structure. Mov Disord 9: 76-83
51. Mathew RT, Yang L, Beal MF (1997) S-methylthiocitrulline, a neuronal nitric oxidase synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp Neurol 143: 282-286
52. McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56: 149-162
53. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S (1994) An immunohistochemical study on alfa-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 35: 204-210
54. Morrish PK, Sawle GV, Brooks DJ (1995) Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 59: 597-600
55. Niznik HB, Fogel EF, Fassos FF, et al. (1991) The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 56: 192-198
56. Nurmi E, Bergman J, Eskola O, et al. (2000) Reproducibility and effect of L-dopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cerebr Blood F Met 20: 1604-1609
57. 18F uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 136: 169-173
58. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600
59. Pate BD, Kuwamata T, Yamada T, et al. (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34: 331-338
60. Perese DA, Ulman J, Viola J, Ewing SE, Bankiewicz KS (1989) A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 494: 285-293
61. Piccini P, Morrish PK, Turjanski N, Sawle GV, Burn DJ, Weeks RA, Mark MH, Maraganore DM, Lees AJ, Brooks DJ (1997) Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 41: 222-229
62. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ (1999) The role of inheritance in sporadic Parkinson's disease/evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45: 577-582
63. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
64. Prezdborski S, Kostic V, Jackson-Lewis V, et al. (1992) Transgenic mice with increased Cu/Zn superoxide dismutase activity are resistant to MPTP-induced neurotoxicity. J Neurosci 12: 1658-1667
65. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, et al. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76: 1265-1274
66. PSD (2002) Dopamine transporter brain imaging to assess the effect of pramipexole vs L-dopa on Parkinson disease progression. JAMA 13: 1653-1661
67. Ravina BM, Fagan SC, Hart RG, et al. (2003) Neuroprotective agents for clinical trials in Parkinson's disease. A systematic assessment. Neurology 60: 1234-1240
68. Ricaurte GA, Irwin I, Forno LS, DeLanney LE, Langston E, et al. (1987) Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403: 43-51
69. Schapira AHV, Cooper JM, Dexter D, et al. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269
70. Schillaci O, Pierantozzi M, Filippi, et al. (2005) The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 19: 169-171
71. Seibyl JP, Marek KL, Quinland D, et al. (1995) Decreased single-Photon emission tomographic [123 I]β-OT striatal uptake correlated with symptom severity in Parkinson's disease. Ann Neurol 38: 589-598
72. Seniuk NA, Tatton WG, Greenwood CE (1990) Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 527: 7-20
73. Sgadò P, Albéri L, Galasso SL, Ramakers GMJ, Smidt MP, Dyck RH, Simon HH (2005) Progressive postnatal degeneration of nigral dopaminergic neurons in Engrailed mutant mice. Science (submitted)
74. Siderowf A, Stern M (2003) Update on Parkinson disease. Ann Intern Med 138: 651-658
75. Simon HH, Saueressig H, Wurst W, Goulding MD, O'Leary DD (2001) Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci 21: 3126-3134
76. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841
77. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34: 324-330
78. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5: 107-110
79. Uversky VN (2004) Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318: 225-241
80. Vander Borght T, Killboum M, Desmond T, Kuhl D, Frey K (1995) The vescicular monoamine transporter is not regulated by dopaminergic drug treatment. Eur J Pharmacol 294: 577-583
81. Vieregge P (1994) Genetic factors in the etiology of idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect 8: 1-37
82. Vingerhoets FJ, Schulzer M, Ruth TJ, et al. (1996) Reproducibility and discriminating ability of fluorine -18-6-fluoro-L-Dopa PET in Parkinson's disease. J Nucl Med 37: 421-426
83. Von Coelln R, Dawson VL, Dawson TM (2004) Parkin-associated Parkinson's disease. Cell Tissue Res 318: 175-184
84. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, et al. (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci USA 101: 10744-10749
85. Ward CD (1994) Does selegiline delay the progression of Parkinson's disease? A critical reevaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57: 217-220
86. Youdim MBH, Am OB, Yogev-Falach M, et al. (2005) Rasagiline: neurodegeneration, neuroprotection and mitochondrial permeability transition. J Neurosci Res 79: 172-179
87. Youdim MBH, Lavie L (1994) Selective MAO-A and B inhibitors, radical scavengers and nitric oxide inhibitors in Parkinson's disease. Life Sci 55: 2077-2082
88. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607